No Prescription |
 |
 | ||
|
MINIRIN Concentraid |
|
| ||
No Prescription » Prescription Drugs 11 » MINIRIN Concentraid Nasal desmopressin is used to control the symptoms of a certain type of diabetes insipidus ('water diabetes'; condition in which the body produces an abnormally large amount of urine). Nasal desmopressin is also used to control excessive thirst and the passage of an abnormally large amount of urine that may occur after a head injury or after certain types of surgery. One brand of desmopressin nasal spray (Stimate«) is used to stop bleeding in people who have certain bleeding disorders. Desmopressin is in a class of medications called hormones. It works by replacing vasopressin a hormone that is normally produced in the body to help balance the amount of water and salt.Nasal desmopressin comes as a liquid that is administered into the nose through a rhinal tube (thin plastic tube that is placed in the nose to administer medication) and as a nasal spray. It is usually used one to three times a day. If you are using desmopressin nasal spray (Stimate) to treat bleeding problems your doctor will tell you when you should use the medication. Try to use nasal desmopressin at around the same time(s) every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Use nasal desmopressin exactly as directed. Do not use more or less of it or use it more often than prescribed by your doctor.If you are using desmopressin nasal spray (Stimate) to treat bleeding problems you will receive your first dose in a doctor's office. Your doctor will order laboratory tests to see if this dose was effective before you begin to use the medication on your own.Your doctor may start you on a low dose of nasal desmopressin and gradually increase your dose. Follow these directions carefully.After you use nasal desmopressin for 6 months or longer you may find that the medication does not work as well as it worked at the beginning of your treatment. Call your doctor if this happens.If you will be using the nasal spray you should check the manufacturer's information to find out how many sprays your bottle contains. Keep track of the number of sprays you use not including the priming sprays. Throw away the bottle after you use the stated number of sprays even if it still contains some medication because additional sprays might not contain a full dose of medication. Do not try to transfer the leftover medication to another bottle. Buy MINIRIN Concentraid and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About MINIRIN Concentraid: Product Type: Prescription Drugs 11 MINIRIN ( Concentraid DDAVP Stimate Generic Desmopressin ) MINIRIN (Concentraid DDAVP Stimate Generic Desmopressin) Concentraid DDAVP Stimate Generic Desmopressin 10mcg metered spray/0.1MG 2.5ML 0.1mg 30 Tablets 0.1mg 90 Tablets 0.2mg 30 Tablets 0.2mg 60 Tablets Concentraid DDAVP Stimate Generic Desmopressin MINIRIN
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
